Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | IL1B | P01584 | 4/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334596 | 1.00 | ALDH1A1 (0.46) | ALDH1A1IL1BP2RX7SMN1; SMN2HPGD | |
| SCHEMBL2337252 | 1.00 | ALDH1A1 (0.46) | ALDH1A1IL1BP2RX7SMN1; SMN2HPGD | |
| SCHEMBL2333743 | 0.87 | HTR4 (0.46) | IL1BP2RX7HTR4 | |
| SCHEMBL8235725 | 0.85 | IL1B (0.42) | IL1BP2RX7HTR4 | |
| SCHEMBL8235737 | 0.84 | ALDH1A1 (0.48) | ALDH1A1IL1BP2RX7SMN1; SMN2HPGD | |
| SCHEMBL19453109 | 0.82 | HTR3E (0.51) | ALDH1A1IL1BP2RX7SMN1; SMN2HPGD | |
| SCHEMBL16098421 | 0.82 | HTR3E (0.51) | ALDH1A1IL1BP2RX7SMN1; SMN2HPGD | |
| SCHEMBL2335322 | 0.82 | HTR4 (0.47) | ALDH1A1IL1BP2RX7HPGDHTR4 | |
| SCHEMBL2329698 | 0.82 | HTR4 (0.47) | ALDH1A1IL1BP2RX7HPGDHTR4 | |
| SCHEMBL2331334 | 0.82 | HTR4 (0.47) | ALDH1A1IL1BP2RX7HPGDHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | claimed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | claimed |
| CN-102753172-A | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC | 2012-10-24 | — | — | CN | claimed |
| WO-2011099305-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RAQUALIA PHARMA INC. (JP) | 2011-08-18 | — | — | WO | claimed |
| EP-2533780-B1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | ASKAT INC (JP) | 2017-08-23 | — | — | EP | disclosed |
| US-8980922-B2 | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RQUALIA PHAMRA INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| EP-2533780-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RaQualia Pharma Inc (JP) | 2012-12-19 | — | — | EP | disclosed |
| CN-102753172-A | 5-HT4 receptor agonists for the treatment of dementia | RAQUALIA PHARMA INC | 2012-10-24 | — | — | CN | disclosed |
| WO-2011099305-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | RAQUALIA PHARMA INC. (JP) | 2011-08-18 | — | — | WO | disclosed |
| WO-2007068739-A1 | 4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322826-A1 | 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA | HTR4, HTR5A, HTR1A | ALDH1A1 2091/4885IL1B 1554/4885P2RX7 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.